Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Joseph F. Dasta, Shirin Sundar, Sandra Chase, Melissa Lingohr-Smith & Jay Lin. (2018) Economic impact of tolvaptan treatment vs. fluid restriction based on real-world data among hospitalized patients with heart failure and hyponatremia. Hospital Practice 46:4, pages 197-202.
Read now
Read now
Alpesh N. Amin, Jesse D. Ortendahl, Amanda L. Harmon, Siddhesh A. Kamat, Robert A. Stellhorn, Sandra L. Chase & Shirin V. Sundar. (2018) Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia. Current Medical Research and Opinion 34:3, pages 559-566.
Read now
Read now
Varun Ramamohan, Deirdre Mladsi, Naoko Ronquest, Siddhesh Kamat & Susan Boklage. (2017) An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia. Hospital Practice 45:3, pages 111-117.
Read now
Read now
Gina Nicholson, Shravanthi R Gandra, Ronald J Halbert, Akshara Richhariya & Robert J Nordyke. (2016) Patient-level costs of major cardiovascular conditions: a review of the international literature. ClinicoEconomics and Outcomes Research 8, pages 495-506.
Read now
Read now
Alpesh Amin, Amanda Bruno, Jeffrey Trocio, Jay Lin & Melissa Lingohr-Smith. (2015) Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Journal of Medical Economics 18:6, pages 399-409.
Read now
Read now
Alpesh Amin, Yonghua Jing, Jeffrey Trocio, Jay Lin, Melissa Lingohr-Smith & John Graham. (2014) Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. Journal of Medical Economics 17:11, pages 763-770.
Read now
Read now
Alpesh Amin, Steven Deitelzweig, Rudell Christian, Keith Friend, Jay Lin & Timothy J. Lowe. (2013) Healthcare resource burden associated with hyponatremia among patients hospitalized for heart failure in the US. Journal of Medical Economics 16:3, pages 415-420.
Read now
Read now
Steve Deitelzweig, Alpesh Amin, Yonghua Jing, Dinara Makenbaeva, Daniel Wiederkehr, Jay Lin & John Graham. (2012) Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. Journal of Medical Economics 15:4, pages 776-785.
Read now
Read now
Joseph F Dasta, Jun R Chiong, Rudell Christian, Keith Friend, Melissa Lingohr-Smith, Jay Lin & Irving B Cassidy. (2012) Update on tolvaptan for the treatment of hyponatremia. Expert Review of Pharmacoeconomics & Outcomes Research 12:4, pages 399-410.
Read now
Read now
Articles from other publishers (20)
Yasuhisa Nakao, Hiroshi Kawakami, Makoto Saito, Katsuji Inoue, Shuntaro Ikeda & Osamu Yamaguchi. (2022) Cost-Effectiveness of long-term tolvaptan administration for chronic heart failure treatment in Japan. Journal of Cardiology 79:3, pages 408-416.
Crossref
Crossref
Meaghan Lunney, Marinella Ruospo, Patrizia Natale, Robert R Quinn, Paul E Ronksley, Ioannis Konstantinidis, Suetonia C Palmer, Marcello Tonelli, Giovanni FM Strippoli & Pietro Ravani. (2020) Pharmacological interventions for heart failure in people with chronic kidney disease. Cochrane Database of Systematic Reviews 2020:2.
Crossref
Crossref
Alpesh N Amin, Jesse D Ortendahl, Amanda L Harmon, Siddhesh A Kamat, Robert A Stellhorn, Sandra L Chase & Shirin V Sundar. (2019) Costs associated with unplanned readmissions among patients with heart failure with and without hyponatremia. American Journal of Health-System Pharmacy 76:6, pages 374-380.
Crossref
Crossref
Ryo Matsuura & Kent Doi. 2019. Critical Care Nephrology. Critical Care Nephrology
364
368.e1
.
Samuel H. Sigal, Alpesh Amin, Joseph A. Chiodo & Arun Sanyal. (2018) Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry. Canadian Journal of Gastroenterology and Hepatology 2018, pages 1-9.
Crossref
Crossref
Evi V Nagler, Maria C Haller, Wim Van Biesen, Raymond Vanholder, Jonathan C Craig & Angela C Webster. (2018) Interventions for chronic non-hypovolaemic hypotonic hyponatraemia. Cochrane Database of Systematic Reviews 2018:6.
Crossref
Crossref
Yukihito Sato. 2018. Therapeutic Strategies for Heart Failure. Therapeutic Strategies for Heart Failure
73
92
.
Clare Jamookeeah, Paul Robinson, Karl O’Reilly, Johan Lundberg, Martin Gisby, Michael Ländin, Jakob Skov & David Trueman. (2016) Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden. BMC Endocrine Disorders 16:1.
Crossref
Crossref
Teruhiko Imamura, Koichiro Kinugawa, Daisuke Nitta & Issei Komuro. (2016) Tolvaptan Reduces Long-Term Total Medical Expenses and Length of Stay in Aquaporin-Defined Responders. International Heart Journal 57:5, pages 593-599.
Crossref
Crossref
Alpesh Amin, Yonghua Jing, Jeffrey Trocio, Jay Lin, Melissa Lingohr-Smith & John Graham. (2014) Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results. Journal of Thrombosis and Thrombolysis 40:2, pages 131-138.
Crossref
Crossref
Min-Young Lee, Hee-Jin Kang, Se-Young Park, Hye-Lin Kim, Euna Han & Eui-Kyung Lee. (2014) Cost-effectiveness of Tolvaptan for Euvolemic or Hypervolemic Hyponatremia. Clinical Therapeutics 36:9, pages 1183-1194.
Crossref
Crossref
Jonathan D. Cicci, Brent N. Reed, Elizabeth B. McNeely, Akinyemi Oni-Orisan, J. Herbert Patterson & Jo E. Rodgers. (2014) Acute Decompensated Heart Failure: Evolving Literature and Implications for Future Practice. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34:4, pages 373-388.
Crossref
Crossref
Il Hwan OhGheun-Ho Kim. (2014) Clinical Application of V2 Receptor Antagonists. Korean Journal of Medicine 86:6, pages 686.
Crossref
Crossref
Satoshi Suzuki, Akiomi Yoshihisa, Takayoshi Yamaki, Koichi Sugimoto, Hiroyuki Kunii, Kazuhiko Nakazato, Yukihiko Abe, Tomiyoshi Saito, Takayuki Ohwada, Hitoshi Suzuki, Shu‐ichi Saitoh, Isao Kubota & Yasuchika Takeishi. (2013) Acute heart failure volume control multicenter randomized (AVCMA) trial: Comparison of tolvaptan and carperitide. The Journal of Clinical Pharmacology 53:12, pages 1277-1285.
Crossref
Crossref
Jonathan D. Breshears, Bowen Jiang, Nathan C. Rowland, Sandeep Kunwar & Lewis S. Blevins. (2013) Use of conivaptan for management of hyponatremia following surgery for Cushing's disease. Clinical Neurology and Neurosurgery 115:11, pages 2358-2361.
Crossref
Crossref
Alessandro Peri. (2013) The Use of Vaptans in Clinical Endocrinology. The Journal of Clinical Endocrinology & Metabolism 98:4, pages 1321-1332.
Crossref
Crossref
Bruce Friedman & Joshua Cirulli. (2013) Hyponatremia in critical care patients: Frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan. Journal of Critical Care 28:2, pages 219.e1-219.e12.
Crossref
Crossref
Masatsugu Hori. (2013) Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure. Future Cardiology 9:2, pages 163-176.
Crossref
Crossref
Aaron Begue, Janine Overcash, Ronald Lewis, Sheri Blanchard, Taletha M. Askew, Charles P. Borden, Toni Semos, Andrea D. Yagodich & Patrick Ross. (2012) Retrospective Study of Multidisciplinary Rounding on a Thoracic Surgical Oncology Unit. Clinical Journal of Oncology Nursing 16:6, pages E198-E202.
Crossref
Crossref
T. Frouget. (2012) Syndrome d’antidiurèse inappropriée (sécrétion inappropriée d’hormone antidiurétique). La Revue de Médecine Interne 33:10, pages 556-566.
Crossref
Crossref